Abstract

To develop public-health policies that extend the lifespan of affordable anti-malarial drugs as effective treatment options, it is necessary to understand the evolutionary processes leading to the origin and spread of mutations conferring drug resistance in malarial parasites. We built a population-genetic model for the emergence of resistance under combination drug therapy. Reproductive cycles of parasites are specified by their absolute fitness determined by clinical parameters, thus coupling the evolutionary-genetic with population-dynamic processes. Initial mutations confer only partial drug-resistance. Therefore, mutant parasites rarely survive combination therapy and within-host competition is very weak among parasites. The model focuses on the early phase of such unsuccessful recurrent mutations. This ends in the rare event of mutants enriching in an infected individual from which the successful spread of resistance over the entire population is initiated. By computer simulations, the waiting time until the establishment of resistant parasites is analysed. Resistance spreads quickly following the first appearance of a host infected predominantly by mutant parasites. This occurs either through a rare transmission of a resistant parasite to an uninfected host or through a rare failure of drugs in removing “transient” mutant alleles. The emergence of resistance is delayed with lower mutation rate, earlier treatment, higher metabolic cost of resistance, longer duration of high drug dose, and higher drug efficacy causing a stronger reduction in the sensitive and resistant parasites’ fitnesses. Overall, contrary to other studies’ proposition, the current model based on absolute fitness suggests that aggressive drug treatment delays the emergence of drug resistance.

Highlights

  • Effective antimalarial drugs remain a major means of controlling human malarias

  • The major objective here is to identify evolutionary pathways leading to the rise of resistance and factors qualitatively influencing these pathways It is to be examined if change in absolute values of parameters lead to qualitative changes in the dynamics

  • This study proposed a model of the evolution of anti-malarial drug resistance which focuses on the early stochastic processes including de novo mutations conferring partial resistance against combination therapy and their successful propagation under weak intra-host competition

Read more

Summary

Introduction

Control efforts of Plasmodium falciparum, the most virulent form of human malaria, have been thwarted by the rapid evolution of drug resistance. In the 1990s, CQ became ineffective to treat P. falciparum malaria in many endemic areas worldwide. It was replaced as a first-line treatment by sulphadoxine-pyrimethamine (SP), a combination of two drugs. The rationale behind combination therapies is that a parasite acquires resistance only when it carries independent mutations, each of which acts against a single drug [1,7,8]. The recent observation of weak ACT resistance in Southeast Asia [9,10,11,12,13,14] may forecast further evolution of clinical resistance that threatens successful control interventions and highlights the importance of understanding the mechanisms driving drug resistance under combination therapy

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.